For the fifth year in a row, Culver's of Rock Falls has been recognized by the Culver's franchise for its dedication to ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

AAM said the law sets up a process under which a drug would have price controls applied before a generic or biosimilar even ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

Pyzchiva, a treatment for plaque psoriasis, Crohn's disease, active psoriatic arthritis and ulcerative colitis, is Samsung ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...